Bellevue Group AG increased its holdings in Silk Road Medical, Inc (NASDAQ:SILK – Free Report) by 5.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,518,230 shares of the company’s stock after acquiring an additional 82,548 shares during the quarter. Bellevue Group AG owned about 3.85% of Silk Road Medical worth $27,814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also added to or reduced their stakes in the company. CWM LLC boosted its position in Silk Road Medical by 151.5% in the fourth quarter. CWM LLC now owns 2,563 shares of the company’s stock worth $31,000 after purchasing an additional 1,544 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Silk Road Medical by 1,293.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,523 shares of the company’s stock worth $31,000 after purchasing an additional 2,342 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Silk Road Medical by 879.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,210 shares of the company’s stock valued at $52,000 after acquiring an additional 3,780 shares during the last quarter. Quest Partners LLC purchased a new position in shares of Silk Road Medical in the fourth quarter valued at $62,000. Finally, Tower Research Capital LLC TRC raised its stake in Silk Road Medical by 369.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,834 shares of the company’s stock valued at $96,000 after purchasing an additional 6,165 shares in the last quarter.
Silk Road Medical Trading Up 0.0 %
Silk Road Medical stock traded up $0.01 during trading on Friday, hitting $27.02. The company had a trading volume of 1,077,613 shares, compared to its average volume of 1,237,167. The company has a current ratio of 11.05, a quick ratio of 9.62 and a debt-to-equity ratio of 0.52. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -19.72 and a beta of 1.52. Silk Road Medical, Inc has a 1-year low of $6.08 and a 1-year high of $27.19. The company’s 50 day simple moving average is $24.75 and its 200-day simple moving average is $19.94.
Analyst Ratings Changes
A number of analysts have recently weighed in on the stock. Stifel Nicolaus restated a “hold” rating and issued a $27.50 target price (up from $23.00) on shares of Silk Road Medical in a report on Wednesday, July 17th. Argus lowered shares of Silk Road Medical from a “buy” rating to a “sell” rating in a research report on Thursday, July 11th. Piper Sandler upped their price target on shares of Silk Road Medical from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. lifted their target price on Silk Road Medical from $19.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, May 1st. Finally, Lake Street Capital reissued a “hold” rating and set a $27.50 price objective (down from $28.00) on shares of Silk Road Medical in a report on Tuesday, June 18th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $21.50.
Read Our Latest Stock Report on Silk Road Medical
About Silk Road Medical
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.
Read More
- Five stocks we like better than Silk Road Medical
- Bank Stocks – Best Bank Stocks to Invest In
- Is Crypto Cool Again? What Stocks You Should Be Watching
- What is the Shanghai Stock Exchange Composite Index?
- Why Call Options Volume for These 2 Stocks Spiked Together
- What Are the U.K. Market Holidays? How to Invest and Trade
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding SILK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silk Road Medical, Inc (NASDAQ:SILK – Free Report).
Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.